Generic Name and Formulations:
Measles, mumps, rubella, and varicella viruses live, attenuated; lyophilized pwd for SC inj after reconstitution; contains neomycin (trace), human albumin; preservative-free.
Merck & Co., Inc.
Indications for PROQUAD:
Measles, mumps, rubella, and varicella immunization; may be used if a 2nd dose of measles, mumps, rubella, and varicella vaccine is needed.
Give SC in deltoid area or upper anterolateral thigh. <12 months or ≥13yrs: not recommended. 12 months–12yrs: 1 dose of 0.5mL. If a 2nd dose is needed, give at 4–6yrs.
Egg, gelatin, or neomycin hypersensitivity. Blood dyscrasias. Leukemia, lymphoma, or other bone marrow or lymphatic malignancy. Primary or acquired immunodeficiency. Family history of congenital or hereditary immunodeficiency. Immunosuppressant therapy. Active untreated tuberculosis. Fever >101.3°F. Pregnancy (Cat.X); avoid pregnancy for 3 months after vaccination.
Have epinephrine inj (1:1000) available. History of febrile convulsions or cerebral injury. Thrombocytopenia. Avoid contact with high-risk individuals susceptible to varicella for 6 weeks after vaccination. Post-exposure prophylaxis for measles, mumps, rubella, or varicella. HIV-infected children. Contains albumin; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease). Nursing mothers: not recommended.
Immunosuppressants (see Contraindications). Avoid salicylates for 6 weeks after vaccination. Defer vaccination for at least 3 months after blood or plasma transfusions or immune globulins. Avoid immune globulin administration for 1 month after vaccination. Separate dosing of measles-containing vaccine by 1 month. If 2nd dose of varicella-containing vaccine needed, separate by 3 months. Concomitant other vaccines: see full labeling. May interfere with tuberculin skin test.
Inj site reactions, fever, irritability, rash; others.
Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—10 (w. diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma